Multinuclear NMR spectroscopy and antitumor activity of novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines

Novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines have been synthesized and characterized by infrared and multinuclear magnetic resonance spectroscopic techniques (1H, 13C, 15N, 195Pt). The complexes are of two types: [PtCl2(L)2] and [PtCl2(NH3)(L)], where L=5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp) and 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp). Significant 15N NMR upfield shifts (92-95 ppm) were observed for N(3) atom indicating this nitrogen atom as a coordination site. The molecular structure suggest that Pt(II) ion has the square planar geometry with N(3) bonded 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines, N-bonded second ligand (NH3 for cis-[PtCl2(NH3)(L)] or, respectively, 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines for cis-[PtCl2L2]) and two cis chloride anions. The antiproliferative activity in vitro of complexes (1-4) have been tested against the cells of four human cell lines: SW707 rectal adenocarcinoma, A549 non-small cell lung carcinoma, T47D breast cancer and HCV29T bladder cancer. The results indicate a moderate antiproliferative activity of (4) against the cells of rectal, breast and bladder cancer and a marked and selective cytotoxic effect of (1-3) against the cells of all studied human cancer lines.     

Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines

Antagonism of the adenosine A_2a receptor offers great promise in the treatment of Parkinson’s disease. In the course of exploring pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A_2A antagonists, which led to clinical candidate SCH 420814, we prepared 1,2,4-triazolo[1,5-c]pyrimidines with potent and selective (vs A₁) A_2a antagonist activity, including oral activity in the rat haloperidol-induced catalepsy model. Structure–activity relationships and plasma levels are described for this series.     

Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones

Antagonism of the adenosine A_2A receptor affords a possible treatment of Parkinson’s disease. In the course of investigating pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A_2A antagonists, we prepared [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones with potent and selective (vs A₁) A_2A antagonist activity. Structure-activity relationships are described for this series.     

1,2,4-triazolo[4,3-a]pyrimidines: a new kind of ligands. Structure of the silver(I) dimer with the 7-oxo derivative

This paper describes the silver dinuclear complex [Ag₂L₂(NO₃)₂] · 2H₂O, where L represents the bridging ligand 7,8-dihydro-7-oxo-1,2,4-triazolo[4,3-a]pyrimidine, this being the first example of a coordination compound of a 1,2,4-triazolo[4,3-a]pyrimidine derivative. As a difference with the most studied 1,2,4-triazolo[1,5-a]pyrimidine derivatives, the coordination takes place through the contiguous nitrogen atoms of the triazole ring, closing a six member Ag₂N₄ core with a higher intermetallic distance, 3.4791(3) Å. Linear coordination of silver is not possible in this geometry, so flat trigonal coordination involving also the nitrate counteranion is found instead.     

Synthesis, spectroscopical characterization and the biological activity in vitro of new platinum(II) complexes with imidazo[1,5-a]-1,3,5-triazine derivatives and dimethylsulfoxide

A series of platinum(II) complexes with 6,8-dimethylimidazo[1,5-a]-1,3,5-triazin-4(3H)-one (6,8-DiMe-4-O-IMT) (I) and 6,8-dimethyl-2-thioxo-2,3-dihydroimidazo[1,5-a]-1,3,5-triazin-4(1H)-one (6,8-DiMe-4-O-2-S-IMT) (II) of formula trans-[PtCl₂(dmso)(6,8-DiMe-4-O-IMT)] (1a) and trans-[PtCl₂(dmso)(6,8-DiMe-4-O-2-S-IMT)] (2a) have been prepared and characterized with ¹H, ¹³C, ¹⁵N, ¹⁹⁵Pt NMR and IR. Significant ¹⁵N NMR upfield coordination shifts (81-96 ppm) of N(7) atom indicate this nitrogen atom as a coordination site. The multinuclear NMR and IR spectra indicate the square planar geometry with N(7) bonded heterocycles, S-bonded dimethylsulfoxide and two trans chloride anions. The platinum(II) complexes were tested for their antiproliferative activity in vitro against the cells of four human cell lines: SW707 rectal adenocarcinoma, A549 non-small cell lung carcinoma, T47D breast cancer and HCV29T bladder cancer. The activity of (1a, 2a) was lower than that of cisplatin.     

A dinuclear silver compound with 5,6,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine with a short Ag-Ag bond. Synthesis, characterization, single-crystal structure analysis and cytostatic activity

A new dinuclear coordination compound with the ligand 5,6,7-trimethyl[1,2,4]triazolo[1,5-a]pyrimidine (abbreviated as tmtp) is described, together with its 3D crystal structures and spectroscopic properties. The compound shows a high cytostatic activity in ovarian cancer cell lines.The solid state structure of the compound is dinuclear based, in which the ligand tmtp uses two nitrogens (N3 and N4) to chelate to two different Ag(I) ions. The Ag-Ag distance is relatively short (3.109 Å), but is considered as too long for M-M bonding. The Ag(I) coordination is completed by weakly coordinated, asymmetric bidentate nitrate anions (Ag-O = 2.481-2.819 Å).     

One-dimensional zinc(II) polymers with 4,6-dimethyl-1,2,3-triazolo[4,5-d]pyrimidin-5,7-dionato built by bipyridyl-based ligands acting as spacers both in the first and in the second sphere

Three solids formed by the reaction of the hexaaquazinc(II) salt of 4,6-dimethyl-1,2,3-triazolo[4,5-d]pyrimidin-5,7-diona (Hdmax) and the potentially bridging ligands 1,2-bis(4-pyridyl)ethane (bpe), 1,3-bis(4-pyridyl)propane (bpp) and trans-1,2-bis(4-pyridyl)ethene (bpethe) are described. The crystal structure of those containing bpe and bpethe has been solved by X-ray diffraction turning out to be one-dimensional polymers with zigzag (bpe) or linear (bpethe) disposition of the metal atoms. The triazolopyrimidinato anion is in both cases monodentately coordinated through the N atom furthest from the pyrimidine ring whereas the bipyridyl ligands bridge through their N atoms consecutive metal atoms in the polymer. For the bpethe compound, an additional non-coordinated molecule of the spacer per Zn atom is present, accepting H-bonds from coordinated water molecules and linking in this way the one-dimensional chains into a two-dimensional superstructure. Therefore, bpethe acts as spacer both in the first and second coordination spheres.     

6-Nitrotriazolo[1,5-<Emphasis Type="Italic">a</Emphasis>]pyrimidines as promising structures for pharmacotherapy of septic conditions

Promising 6-nitro-1,2,4-triazolo[1,5-a]pyrimidine analogues, structural analogues of synthetic inhibitors of adenosine receptors, were sorted out on the basis of quantum-chemical calculations. The compounds were synthesized by nitration and chlorodeoxygenation reactions. The in vivo activity of 6-nitroheterocycles was studied and the affinity to adenosine receptor A_2A was demonstrated in regard to septic conditions.     

Synthesis and biological evaluation of 7-(aminoalkyl)pyrazolo[1,5-a]pyrimidine derivatives as cathepsin K inhibitors

A series of novel 7-aminoalkyl substituted pyrazolo[1,5-a]pyrimidine derivatives were synthesized and tested for inhibition of cathepsin K. The synthetic methodology comprises cyclization of 5-aminopyrazoles with N-Boc-α-amino acid-derived ynones followed by transformation of the ester and the Boc-amino functions. It allows for easy diversification of the pyrazolo[1,5-a]pyrimidine scaffold at various positions. Molecular docking studies with pyrazolo[1,5-a]pyrimidine derivatives were also performed to elucidate the binding mode in the active site of cathepsin K. The synthesized compounds exhibited moderate inhibition activity (K_i ≥ 77 μM).     

Synthesis, characterization, crystal structures and in vitro antistaphylococcal activity of organotin(IV) derivatives with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidine

New organotin(IV) complexes of 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp) and 5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp) with 1:1 and/or 1:2 stoichiometry were synthesized and investigated by X-ray diffraction, FT-IR and ¹¹⁹Sn Mössbauer in the solid state and by ¹H and ¹³C NMR spectroscopy, in solution. Moreover, the crystal and molecular structures of Et₂SnCl₂(dbtp)₂ and Ph₂SnCl₂(EtOH)₂(dptp)₂ are reported. The complexes contain hexacoordinated tin atoms: in Et₂SnCl₂(dbtp)₂ two 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine molecules coordinate classically the tin atom through N(3) atom and the coordination around the tin atom shows a skew trapezoidal structure with axial ethyl groups. In Ph₂SnCl₂(EtOH)₂(dptp)₂ two ethanol molecules coordinate tin through the oxygen atom and the 5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine molecules are not directly bound to the metal center but strictly H-bonded, through N(3), to the OH group of the ethanol moieties; Ph₂SnCl₂(EtOH)₂(dptp)₂ has an all-trans structure and the C-Sn-C fragment is linear. On the basis of Mössbauer data, the 1:2 diorganotin(IV) complexes are advanced to have the same structure of Et₂SnCl₂(dbtp)₂, while Me₂SnCl₂(dptp)₂ to have a regular all-trans octahedral structure. A distorted cis-R₂ trigonal bipyramidal structure is assigned to 1:1 diorganotin(IV) complexes. The in vitro antibacterial activities of the synthesized complexes have been tested against a group of reference pathogen micro-organisms and some of them resulted active with MIC values of 5 μg/mL, most of all against staphylococcal strains, which shows their inhibitory effect.     

Synthesis and characterization of Mg(II), Mn(II), Zn(II) and Cd(II) complexes with a new heptaaza Schiff base pendant-armed macrocycle: X-ray crystal structure, NMR and computational study

New 2-aminoethyl pendant-armed Schiff base macrocyclic complexes, [ML⁷]²⁺ (M = Mn(II), Mg(II), Zn(II) and Cd(II)), have been prepared via M(II) templated [1 + 1] cyclocondensation of 2,6-diacetylpyridine with a new branched hexamine, N,N,N′,N′-tetrakis(2-aminoethyl)-2,2-dimethylpropane-1,3-diamine. The ligand is a 16-membered pentaaza macrocycle having two 2-aminoethyl pendant arms [L⁷ is 2,14-dimethyl-6,10-bis(2-aminoethyl)-3,6,10,13,19-pentaazabicyclo[13.3.1]8,8-dimethylnonadeca-1(19),2,13,15,17-pentaene]. The crystal structures of [MnL⁷]²⁺ and [MgL⁷]²⁺ were determined from X-ray diffraction data. The geometry of the coordination sphere of complexes is a slightly distorted pentagonal bipyramid with the metal ion located within a pentaaza macrocycle and two pendant amines coordinating on opposite sides. All complexes were characterized by IR, microanalysis and except of [MnL⁷]²⁺ by ¹H NMR, ¹³C NMR, DEPT135, COSY(H, H) and HMQC spectroscopy. The data indicate that the structure is pentagonal bipyramidal in each case. The structure of all complexes has also been theoretically studied by ab initio Hartree-Fock and density functional theory methods.     

Copper (II) and cobalt (II) complexes of chiral tetrathiafulvalene-oxazoline (TTF-OX) and tetrathiafulvalene-thiomethyl-oxazoline (TTF-SMe-OX) derivatives

Synthesis and single crystal X-ray structures of the first paramagnetic transition metal complexes containing chiral ethylenedithio-tetrathiafulvalene-oxazoline (EDT-TTF-OX) 1a-c and ethylenedithio-tetrathiafulvalene-thiomethyloxazoline 2 (EDT-TTF-(SMe)OX) ligands based on copper (II) and cobalt (II) are described. The racemic [EDT-TTF-OX][Cu(hfac)₂] complex 3a crystallizes in the triclinic centrosymmetric space group , whereas the enantiopure counterparts 3b-c crystallize in the triclinic non-centrosymmetric space group P1. Cu(II) adopts a distorted square pyramidal coordination geometry, a much weaker Cu?S_TTF interaction also being identified. The same coordination pattern around Cu(II) is observed in the complex [(rac)-EDT-TTF-(SMe)OX][Cu(hfac)₂] (4) in spite of the bidentate nature of the redox active ligand. DFT theoretical calculations afforded two equilibrium configurations for a corresponding model complex, in which the metal centre establishes secondary coordination either with one S_TTF or with the SMe group. The same ligand coordinates the cobalt (II) to afford the octahedral complex [(rac)-EDT-TTF-(SMe)OX][Co(hfac)₂] (5). In all these novel complexes, the paramagnetic centres are structurally and magnetically isolated. Cyclic voltammetry measurements show the stability of the radical cation species.     

Solvent-dependent 2D-coordination polymers of Cu(I) containing a bridging triazolopyrimidine ligand

Two 2D-polymers of Cu(I), [Cu₂(μ-tp)(CH₃CN)(μ-I)(μ₃-I)]_n (1) and [Cu₂(μ-tp)(μ₃-I)₂]_n (2), both obtained from the reaction between copper iodide and 1,2,4-triazolo[1,5-a]pyrimidine (tp) in the presence of KI are described. While in compound 1, tp acts as bridging ligand via N1 and N3 between chair-like [Cu₄I₄] units, in compound 2, tp moieties are placed at both sides of a [Cu_nI_n] kinked layer, displaying also a bridging mode but, in this case, through its atoms N3 and N4. These structural differences between both compounds seem to be due to the solvent of crystallization, being acetonitrile for 1 and water for 2. These polymers are the first examples of Cu(I) compounds based on the nucleobase-analog ligand tp.     

Platinum(II) complexes of pyrimidine-derived ligands

A series of new Pt(II) complexes of hydrazinouracils were synthesized and studied. The complexes have the general formula [Pt₂L2^?Cl₂]nH₂O, where L^? is a deprotonated molecule of a ligand, n = 1?3 and there are two bridging chloride ions. The ligands are bonded through the amino group of the hydrazine residue and the nitrogen atom of the pyrimidine cycle. From ¹H NMR data it is concluded that the preferred type of coordination is Pt- N(3), hydrazine chelation, which is characteristic for solid complexes. Although the participation of the N(1) atom in formation on the polynuclear complexes is possible, it may be that N(1) coordination occurs only in solutions.     

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2

Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo[1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors.     

Structural studies on zinc(II) complexes with 2-benzoylpyridine-derived hydrazones

2-Benzoylpyridine-phenylhydrazone (H2BzPh), 2-benzoylpyridine-para-chloro-phenylhydrazone (H2BzpClPh), and 2-benzoylpyridine-para-nitro-phenyl (H2BzpNO₂Ph) hydrazone were obtained and fully characterized, as well as their zinc(II) complexes [Zn(H2BzPh)Cl₂] (1), [Zn(H2BzClPh)Cl₂] (2) and [Zn(H2BzpNO₂Ph)Cl₂] (3). During the syntheses of complex 1 a second product crystallized, which was characterized as [Zn(2BzPh)₂] (1a). Upon re-crystallization in 1:9 DMSO:acetone conversion of 2 into [Zn(H2BzpClPh)Cl₂] · H₂O (2a) and of 3 into [Zn(2BzpNO₂Ph)Cl(DMSO)] (3a) occurred. The crystal structures of 1a, 2a and 3a were determined. In 1a the two nearly perpendicular H2BzPh ligands give rise to a distorted octahedral environment around the metal. The 5-fold coordination around the metal is completed with two chloride ions in 2a and with one chloride and one oxygen atom from DMSO in 3a.     

Monotheophylline and monotheophyllinato complexes of palladium(II) and their interactions with nucleosides

The interaction of potassium tetrachloropalladate(II) with theophylline in a 1:1 molar ratio resulted in the formation of the monotheophylline (K[Pd(ThH)Cl₃]) or monotheophyllinato ([Pd(Th)Cl]₂) complexes, depending on the solvent and the acidity conditions. In the first complex, theophylline coordinates to Pd(II) as a neutral molecule through its N9 atom, while in the second as a monoanion through both its N7 and O6 atoms. Both complexes react with nucleosides, giving the complexes [Pd(Nucl)(ThH)Cl₂] and [Pd(Nucl)(Th)Cl], respectively. Those complexes with one N(1)H ionizable imino-proton undergo deprotonation and two new series of mixed ligand complexes, [Pd(Nucl − H⁺)(ThH)Cl] and [Pd(Nucl − H⁺(Th)] are formed. In the mixed ligand complexes, theophylline maintains its coordination modes. The nucleosides, on the other hand, exhibit their usual coordination sites; i.e. in the nondeprotonated complexes they coordinate only through their N7 atoms, while in the deprotonated they act as bidentate through both their N7 and O6 atoms. All complexes were characterized with elemental analyses, conductivity measurements and various spectroscopic techniques.     

Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents

The synthesis and SAR of a series of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents are described. This series of 2-heteroarylpyrimidines was developed by modifying a series of anti-tumor [1,2,4]triazolo[1,5-a]pyrimidines and 2-cyanoaminopyrimidines we reported earlier. For the 2-heteroaryl group, the best activity is obtained when the heteroaryl group has a nitrogen atom at the ortho-position to the pyrimidyl core. The structure–activity relationship for the rest of the molecule in this 2-heteroarylpyrimidine series mimics that of the [1,2,4]triazolo[1,5-a]pyrimidine series. Like triazolopyrimidines and 2-cyanoaminopyrimidines, the 2-heteroarylpyrimidines retain the capability to overcome multidrug resistance due to Pgp. Mechanism of action studies showed that the lead compounds behaved in the same manner as triazolopyrimidines and 2-cyanoaminopyrimidines. The lead compounds in this series are more potent than the corresponding triazolopyrimidines in vitro and in vivo. Compound 21 (PTI-868) showed tumor growth inhibition in several nude mouse xenograft models, and was selected to advance to preclinical development.     

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity

The synthesis and antibacterial activities of three chemotypes of DNA supercoiling inhibitors based on imidazolo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine scaffolds that target the ATPase subunits of DNA gyrase and topoisomerase IV (GyrB/ParE) is reported. The most potent scaffold was selected for optimization leading to a series with potent Gram-positive antibacterial activity and a low resistance frequency.     

Nickel(II) and zinc(II) dimonensinates: Single crystal X-ray structure, spectral properties and bactericidal activity

Mononuclear transition metal complexes of the polyether ionophorous antibiotic monensin (monensic acid, MonH) with nickel(II) and zinc(II) were prepared and characterized using single crystal X-ray diffraction and spectral methods. Monensin complexes crystallize as [Ni(Mon)₂(H₂O)₂]·H₂O·5MeCN (1) and [Zn(Mon)₂(H₂O)₂]·H₂O·4.5MeCN (2), respectively, in the monoclinic space group P2₁. Compounds 1 and 2 consist of two monoanionic monensic acid ligands (monensinates) bound in a bidentate coordination mode to the transition metal ion. The metal center is placed in an octahedral environment with monensin anions occupying the equatorial plane of complexes via oxygens of carboxylate and hydroxyl groups located at the both ends of ionophore molecule. The strongly folded antibiotic anions are supported by intramolecular H-bonds, most of them originating from the two aqua ligands attached to the metal(II) ions in axial positions and completing their 6-fold coordination. The bioactivity assay reveals that the presence of divalent metal ion in the monensin complexes influences the biological properties of the ligand and should be taken into account when discussing its mode of action.